PFE Pfizer Inc.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
PFE stock data
()
Calendar
6 Aug 20
14 Aug 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 11.8B | 12.03B | 12.68B | 13.26B | |
| Net income | 3.43B | 3.41B | 7.68B | 5.06B | |
| Diluted EPS | 0.61 | 0.61 | 1.36 | 0.89 | |
| Net profit margin | 29.10% | 28.35% | 60.60% | 38.12% | |
| Operating income* | 4.32B | 4.27B | 11.13B | 4.52B | |
| Net change in cash | -350M | -634M | 1B | -153M | |
| Cash on hand | 1.8B | 2.15B | 2.79B | 1.78B | |
| Cost of revenue | 2.28B | 2.38B | 2.6B | 2.58B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 53.65B | 52.55B | 52.82B | 48.85B | |
| Net income | 11.19B | 21.36B | 7.25B | 6.99B | |
| Diluted EPS | 1.87 | 3.52 | 1.17 | 1.11 | |
| Net profit margin | 20.85% | 40.64% | 13.72% | 14.30% | |
| Operating income* | 13.17B | 13.53B | 9.51B | 10.14B | |
| Net change in cash | -203M | -1.25B | -1.05B | 298M | |
| Cash on hand | 1.14B | 1.34B | 2.6B | 3.64B | |
| Cost of revenue | 11.25B | 11.23B | 12.32B | 9.65B |
Financial data from Pfizer earnings reports. *Asterisk values are approximate.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 6 Aug 20 | Blaylock Ronald E | Common Stock | Buy | Aquire P | No | 38.62 | 1,000 | 38.62K | 13,000 |
| 6 Aug 20 | Blaylock Ronald E | Common Stock | Buy | Aquire P | No | 38.69 | 1,000 | 38.69K | 12,000 |
| 6 Aug 20 | Blaylock Ronald E | Common Stock | Buy | Aquire P | No | 38.51 | 1,500 | 57.77K | 11,000 |
| 6 Aug 20 | Blaylock Ronald E | Common Stock | Buy | Aquire P | No | 38.56 | 2,500 | 96.4K | 9,500 |
| 6 Aug 20 | Blaylock Ronald E | Common Stock | Buy | Aquire P | No | 38.55 | 3,000 | 115.65K | 7,000 |
| 6 Aug 20 | Blaylock Ronald E | Common Stock | Buy | Aquire P | No | 38.49 | 4,000 | 153.96K | 4,000 |
| 31 Jul 20 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 38.48 | 13 | 500.24 | 78,470 |
| 31 Jul 20 | John D Young | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 38.48 | 11 | 423.28 | 47,212 |
| 31 Jul 20 | Rady A Johnson | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 38.48 | 4 | 153.92 | 5,619 |
Institutional ownership Q1 2020
70.4% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2369 |
| Opened positions | 115 |
| Closed positions | 211 |
| Increased positions | 963 |
| Reduced positions | 1091 |
13F shares |
Current |
|---|---|
| Total value | 1.38T |
| Total shares | 3.91B |
| Total puts | 34.5M |
| Total calls | 24.3M |
| Total put/call ratio | 1.4 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 461.98M | $15.08B |
| BLK BlackRock | 424.07M | $13.84B |
| STT State Street | 292.62M | $9.55B |
| Capital World Investors | 224.81M | $7.34B |
| Wellington Management | 218.68M | $7.14B |
| Geode Capital Management | 89.95M | $2.93B |
| BAC Bank of America | 86.67M | $2.83B |
| NTRS Northern Trust | 70.02M | $2.29B |
| State Farm Mutual Automobile Insurance | 56.54M | $1.85B |
| BK Bank of New York Mellon | 56.09M | $1.83B |
Financial report summary
?Competition
Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Cypress Bioscience • Celldex Therapeutics • Poniard Pharmaceuticals • Imclone Systems • Acura Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
AAH, adapted, addressing, Adjuvant, Agent, Albert, automatically, besylate, blinded, Bourla, BRIGHT, broadly, chose, cohort, Cortexyme, cyber, daunorubicin, deeply, Diflucan, dispense, dispensed, dispensing, ehf, England, epidemiological, faith, febrile, fewer, futility, glycoprotein, GmbH, good, gradual, gradually, guarantor, heard, hearing, inconsistent, insulin, intermediary, journal, lifesaving, Lightspeed, loan, London, malware, manifested, maternal, meningococcal, mentioned, messenger, Mexico, misrepresented, mobility, myelosuppressive, Neisseria, Neratinib, neuropathic, neutralizing, neutropenia, NHS, notice, Nyvepria, partnership, peer, phishing, precedent, preclinical, pregabalin, proven, PTC, Puma, RAR, ready, Reddy, regimen, RET, RNA, RSV, safe, sampling, schedule, Scotland, Scottish, SE, Shanghai, shorter, skin, spike, statutory, steady, syncytial, Trump, UK, unconditionally, unnecessary, vitro, withdrawn, young, Zoloft
Removed:
acute, aged, alectinib, ALK, Amneal, amyloid, artificially, Authorisation, autonomy, Avastin, Avillion, azacitidine, Baxter, begin, Ben, bevacizumab, Biotech, capture, cardiovascular, catch, category, Celltrion, ceritinib, cervical, CMA, comprised, consistently, crizotinib, culture, declared, Eurohealth, familial, fine, Genentech, germline, Gland, glioblastoma, Hengrui, Hikma, HR, induction, informed, Janssen, Jiangsu, Kabi, leaving, letter, Lorviqua, media, meglumine, modest, monotherapy, myeloid, NDA, neck, negotiating, Orion, OTC, output, overturned, persistent, pertaining, phenytoin, PLC, polyneuropathy, Precedex, premix, recurrent, retain, saline, Sarl, setting, sodium, solution, spinoff, split, susceptibility, TKI, Tribunal, unresectable, vaccinated, Venue, voluntarily, write, Zirabev
Financial reports
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
Current reports
8-K
Regulation FD Disclosure
6 Aug 20
8-K
Pfizer Reports Second-quarter 2020 Results
28 Jul 20
8-K
Other Events
26 Jun 20
8-K
Entry into a Material Definitive Agreement
1 Jun 20
8-K
Other Events
28 May 20
8-K
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
22 May 20
8-K
Pfizer Prices $4,000,000,000 Debt Offering
19 May 20
8-K
Pfizer Reports First-quarter 2020 Results
28 Apr 20
8-K
Submission of Matters to a Vote of Security Holders
24 Apr 20
8-K
Susan Desmond-hellmann Elected to Pfizer’s Board of Directors
2 Apr 20
Registration and prospectus
425
Business combination disclosure
26 Jun 20
425
Business combination disclosure
18 Jun 20
425
Business combination disclosure
1 Jun 20
424B5
Prospectus supplement for primary offering
20 May 20
FWP
Free writing prospectus
19 May 20
424B3
Prospectus supplement
18 May 20
425
Business combination disclosure
30 Apr 20
424B5
Prospectus supplement for primary offering
26 Mar 20
425
Business combination disclosure
26 Mar 20
FWP
Free writing prospectus
25 Mar 20
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 20
PX14A6G
Letter to shareholders
6 Apr 20
PX14A6G
Letter to shareholders
3 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Mar 20
DEF 14A
Definitive proxy
13 Mar 20
PX14A6G
Letter to shareholders
8 Apr 19
DEFA14A
Additional proxy soliciting materials
2 Apr 19
PX14A6G
Letter to shareholders
21 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
14 Mar 19
Other
CT ORDER
Confidential treatment order
15 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
7 Mar 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
31 Jan 17
NO ACT
No action letter
26 Jan 17
NO ACT
No action letter
10 Jan 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
4
PFIZER / RONALD E BLAYLOCK ownership change
10 Aug 20
3
Initial statement of insider ownership
6 Aug 20
SC 13G
ESSA Pharma / PFIZER ownership change
6 Aug 20
4
PFIZER / JOHN D YOUNG ownership change
3 Aug 20
4
PFIZER / RADY A JOHNSON ownership change
3 Aug 20
4
PFIZER / JENNIFER B. DAMICO ownership change
3 Aug 20
4
PFIZER / ALBERT BOURLA ownership change
3 Aug 20
4
PFIZER / JOHN D YOUNG ownership change
16 Jul 20
4
PFIZER / RADY A JOHNSON ownership change
16 Jul 20
4
PFIZER / JENNIFER B. DAMICO ownership change
16 Jul 20
Patents
APP
Utility
Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile
13 Aug 20
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof.
APP
Utility
GLP-1 Receptor Agonists and Uses Thereof
13 Aug 20
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
APP
Utility
Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
13 Aug 20
This invention relates to a method of treating cancer by administering a PARP inhibitor in combination with a PD-1 axis binding antagonist to a patient in need thereof.
GRANT
Utility
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
11 Aug 20
Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Matthew Merrill Hayward
GRANT
Utility
Anti-IL-2 antibodies and compositions and uses thereof
11 Aug 20
The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ.